ADAR1 Capital Management »

Rafael Hldgs shares owned by ADAR1 Capital Management

Quarter-by-quarter ownership of Rafael Hldgs (RFL) shares owned by ADAR1 Capital Management from 13F filings

Historical chart of ADAR1 Capital Management investment in Rafael Hldgs

Tip: Access up to 7 years of quarterly data

All positions including Rafael Hldgs held by ADAR1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Rafael Hldgs by ADAR1 Capital Management

Quarter filed Position value Share count Share price at filing
2023-12-31 $4.3k 2.4k 1.83

More positions owned by ADAR1 Capital Management

Alnylam Pharmaceuticals (ALNY)
Royalty Pharma Shs Class A (RPRX)
Keros Therapeutics (KROS)
Roivant Sciences SHS (ROIV)
Cytokinetics Com New (CYTK)
Arbutus Biopharma (ABUS)
Bridgebio Pharma (BBIO)
Merrimack Pharmaceuticals In Com New (MACK)
Cerevel Therapeutics Hldng I (CERE)
Mirati Therapeutics
Merck & Co (MRK)
Ascendis Pharma A/s Sponsored Adr (ASND)
Immunovant (IMVT)
Viking Therapeutics (VKTX)
Protagonist Therapeutics (PTGX)

View all positions for ADAR1 Capital Management

Top funds holding Rafael Hldgs

Vanguard Group
Dimensional Fund Advisors
Acuitas Investments
Nantahala Capital Management
Advisor Group Holdings
Citadel Advisors
Two Sigma Investments
Two Sigma Advisers
T. Rowe Price Associates
Millennium Management
Atria Wealth Solutions
Bank of America Corporation
Cutler
Optimum Investment Advisors
Rhumbline Advisers

View all funds holding Rafael Hldgs